{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"61.03","value":"40.3"},{"groupId":"OG001","spread":"79.18","value":"57.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Time to RBC-TI was defined as the time between first dose date and the date of onset of RBC-TI first observed for participants who achieved RBC-TI of ≥ 8 weeks during Week 1 through Week 48","dispersionType":"Standard Deviation","groups":[{"description":"Luspatercept 1.0 mg/Kg SC on Day 1 of each 21-day treatment cycle","id":"OG000","title":"Luspatercept"},{"description":"Placebo (Volume equivalent to experimental arm) SC on Day 1 of each 21-day treatment cycle","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"All participants who achieved RBC-TI ≥ 8 weeks during Week 1 through Week 48","reportingStatus":"POSTED","timeFrame":"From first dose to Week 48 of study treatment","title":"Time to Red Blood Cell Transfusion Independence (RBC-TI) - Week 1 Through Week 48","type":"SECONDARY","unitOfMeasure":"Days"}